At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KTTA Pasithea Therapeutics Corp.
Trading 04-30 12:52:19 EDT
0.6900
+0.0013
+0.19%
High0.6991Low0.6802Vol37.25K
Open0.6900D1 Closing0.6887Amplitude2.74%
Mkt Cap17.21MTradable Cap11.56MTotal Shares24.94M
T/O25.60KT/O Rate0.22%Tradable Shares16.75M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Pasithea Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Dow Jones  ·  04-21
Pasithea Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
GlobeNewswire  ·  04-20
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
Pasithea Therapeutics files Form 3 beneficial ownership statement for Coastlands Capital LP
Reuters  ·  04-18
Pasithea Therapeutics files Form 3 beneficial ownership statement for Coastlands Capital LP
Pasithea Therapeutics Corp reports results for the quarter ended December 31 - Earnings Summary
Reuters  ·  04-03
Pasithea Therapeutics Corp reports results for the quarter ended December 31 - Earnings Summary
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
GlobeNewswire  ·  04-01
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview
Reuters  ·  04-01
Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview
Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock
Simply Wall St.  ·  03-25
Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock
Pasithea Therapeutics Corp expected to post a loss of 18 cents a share - Earnings Preview
Reuters  ·  03-21
Pasithea Therapeutics Corp expected to post a loss of 18 cents a share - Earnings Preview
Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice
TIPRANKS  ·  02-21
Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice
Nasdaq flags Pasithea Therapeutics for failing $1 minimum bid rule
Reuters  ·  02-21
Nasdaq flags Pasithea Therapeutics for failing $1 minimum bid rule
Pasithea Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
Reuters  ·  02-17
Pasithea Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
Pasithea Therapeutics Corporation Held Special Shareholder Meeting
Reuters  ·  01-29
Pasithea Therapeutics Corporation Held Special Shareholder Meeting
Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway
TIPRANKS  ·  01-14
Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway
Pasithea Therapeutics Announces Data Release Timeline for PAS-004 Clinical Trials in NF1 and Advanced Cancer
Reuters  ·  01-13
Pasithea Therapeutics Announces Data Release Timeline for PAS-004 Clinical Trials in NF1 and Advanced Cancer
Pasithea Therapeutics Corp - to Present Nf1-Pn Study Data in H2 2026
THOMSON REUTERS  ·  01-13
Pasithea Therapeutics Corp - to Present Nf1-Pn Study Data in H2 2026
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
GlobeNewswire  ·  01-13
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
Pasithea Therapeutics Unveils Investor Presentation Highlighting Next-Generation MEK Inhibitor PAS-004 for Cancer and NF1
Reuters  ·  01-12
Pasithea Therapeutics Unveils Investor Presentation Highlighting Next-Generation MEK Inhibitor PAS-004 for Cancer and NF1
Pasithea Therapeutics Corporation Announces Date for Upcoming Special Meeting of Stockholders
Reuters  ·  2025-12-20
Pasithea Therapeutics Corporation Announces Date for Upcoming Special Meeting of Stockholders
Pasithea Therapeutics Initiated at Buy by HC Wainwright & Co.
Dow Jones  ·  2025-12-08
Pasithea Therapeutics Initiated at Buy by HC Wainwright & Co.
HC Wainwright Initiates Coverage on Pasithea Therapeutics With Buy Rating, $3 Price Target
MT Newswires Live  ·  2025-12-08
HC Wainwright Initiates Coverage on Pasithea Therapeutics With Buy Rating, $3 Price Target

Introduction

Company Name.
Pasithea Therapeutics Corp.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Issue price:
--